DNAnexus’ cloud-based approach to DNA sequencing
Mountain View, California-based DNANexus operates a cloud-based data analysis platform.
The company’s cloud-based analytics platform is aimed at conducting research into genomics and other big data pursuits, with a collaborative environment facilitating the combination and analysis of real-world and clinical data.
The company’s customers include significant numbers of the largest diagnostics and pharmaceuticals organisations. DNAnexus said its customers use 10 million core processing hours a month, storing 28 petabytes of data - a number up 70% yearly for the past four years.
Since its foundation in 2009, the company has accrued $272.6mn in funding. Its latest Series G, announced earlier this month, saw the company receive $100mn from lead investors Perceptive Advisors and Northpond Ventures, alongside TPG Biotech, Regeneron Pharmaceuticals, GV, Foresite Capital and First Round Capital.
In a press release, Sam Chawla of Perceptive Advisors, said: “DNAnexus has changed how global diagnostics and biomedical R&D markets manage their data and infrastructures. We are impressed with the velocity of DNAnexus’ growth, the breadth of its customers and partners, and the company’s dedication to innovation and technology. It couldn’t be clearer that the integration of clinical and genomic data is driving Precision Medicine, and DNAnexus is leading this space.”
The company said the funds would be used to expand into clinical diagnostics, alongside supporting the platform.
“This financing drives advancement of our data science technologies benefiting our rapidly growing customer base,” said Richard Daly, Chief Executive Officer at DNAnexus. “The next wave of biomedical insights and treatments will be driven by large-scale clinical, multi-omics, and real world data resulting from cross-institutional collaborations. Our customers have continued to grow during the current COVID-19 epidemic using the virtual cloud workspace we provide. The trend toward cloud-based data analysis and collaboration is accelerating, and we are at the right place at the right time to future-proof and serve our customers.”
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.